Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage

Longfei Jia,Min Zhu,Chaojun Kong,Yana Pang,Heng Zhang,Qiongqiong Qiu,Cuibai Wei,Yi Tang,Qi Wang,Ying Li,Tingting Li,Fangyu Li,Qigeng Wang,Yan Li,Yiping Wei,Jianping Jia
DOI: https://doi.org/10.1002/alz.12166
Abstract:Introduction: Exosomes are an emerging candidate for biomarkers of Alzheimer's disease (AD). This study investigated whether exosomal synaptic proteins can predict AD at the asymptomatic stage. Methods: We conducted a two-stage-sectional study (discovery stage: AD, 28; amnestic mild cognitive impairment [aMCI], 25; controls, 29; validation stage: AD, 73; aMCI, 71; controls, 72), a study including preclinical AD (160) and controls (160), and a confirmation study in familial AD (mutation carriers: 59; non-mutation carriers: 62). Results: The concentrations of growth associated protein 43 (GAP43), neurogranin, synaptosome associated protein 25 (SNAP25), and synaptotagmin 1 were lower in AD than in controls (P < .001). Exosomal biomarker levels were correlated with those in cerebrospinal fluid (R2 = 0.54-0.70). The combination of exosomal biomarkers detected AD 5 to 7 years before cognitive impairment (area under the curve = 0.87-0.89). Discussion: This study revealed that exosomal GAP43, neurogranin, SNAP25, and synaptotagmin 1 act as effective biomarkers for prediction of AD 5 to 7 years before cognitive impairment.
What problem does this paper attempt to address?